ClinicalTrials.gg
RecruitingNCT06267729APOLLOUpdated Feb 23, 2026

Study of AZD0754 in Participants With Metastatic Prostate Cancer

A Phase 1/2 interventional study of AZD0754 and AZD2287 in Metastatic Prostate Cancer, sponsored by AstraZeneca. Recruiting at 15 sites in 3 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
38th of 60
60 · median 110
Started
2024
with 2 others
Phase 1/2
11 of 91
6 open now
Primary completion
2026-11
later than 6 of 28 live
Registered
73rd of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 38th largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 1/2, reaches primary completion later than 6 of the 28 other live ones, and was the 73rd registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 130 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

Read the detailed description

This is a first-time in human, multi-center, open label, Phase I/II study of AZD0754 autologous CAR T-cell therapy administered intravenously to participants with metastatic prostate cancer. The study is intended to assess the safety, cellular kinetics, pharmacodynamics, preliminary efficacy, and feasibility of manufacturing AZD0754 for patients with metastatic prostate cancer.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Metastatic Prostate Cancer
  • mCRPC
  • Metastatic castration-resistant prostate cancer
  • CART
  • CAR-T
  • AZD0754
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Participant must be 18 years or older at the time of signing the form.

    Type of Participant and Disease Characteristics

  2. Participants with:

    1. A confirmed diagnosis of adenocarcinoma of the prostate without known neuroendocrine differentiation or small cell features.
    2. Castration-resistant prostate cancer as defined by disease progression despite castration by orchiectomy or ongoing luteinising hormone-releasing hormone analogue. Participants receiving medical castration therapy with gonadotropin releasing hormone analogues should continue this treatment during the study.
    3. Measurable PSA >/=1 ng/mL AND
    4. Evidence of progression within 6 months prior to screening according to one of the following:

    (i) Radiographic disease progression in soft tissue based on Version 1.1 criteria with or without PSA progression as per Prostate Cancer Working Group Criteria 3 (PCWG3) (ii) Radiographic disease progression in bone defined as the appearance of 2 or more new bone lesions on bone scan as per Prostate Cancer Working Group Criteria 3 (PCWG3).

    (iii) Evidence of disease progression in bone according to PSMA PET scan results in tandem with PSA progression according to PCWG3 criteria."

  3. Participant has previously received a NHA (ie, abiraterone, enzalutamide, apalutamide, darolutamide) and a taxane as part of their treatment for prostate cancer (whether before or in the metastatic castration-resistant setting). Participants who are ineligible for taxanes or refuse these therapies may be enrolled at the discretion of the investigator.
  4. For participants with pathogenic mutations in BRCA1 or BRCA2, they must also have received a PARP-inhibitor or be intolerant of this therapy. For participants with non-BRCA HRR deficiency disease, treatment with a PARP-inhibitor is at the discretion of the Investigator based on a risk/benefit analysis and discussion with the participant.
  5. For participants who have high microsatellite instability or deficient DNA mismatch repair they must also have received at least one line of (ie, pembrolizumab), not be eligible for, or be intolerant to therapy as per NCCN or local treatment guidelines.
  6. (ECOG) performance status of 0 or 1 prior to apheresis.
  7. Minimum of > 12 weeks prior to apheresis in the opinion of the Investigator
  8. Adequate organ and marrow function.
  9. Consent and provision of tumour material to assess STEAP2 expression and other correlative biomarkers retrospectively with pre- and post-treatment . Fresh baseline and on-treatment biopsies are required unless these are deemed medically unfeasible. If the participant is unable to undergo fresh biopsy, an archival tumour sample will be required (age of biopsy cannot be greater than 10 years).

Exclusion criteria

Exclusion Criteria:

  1. Participants with weight less than 39 kg
  2. History of another primary except for malignancy treated with curative intent with no known active disease (≥ 2 years) before the first dose of study intervention and of low potential risk for recurrence. Such exceptions include non-melanoma cancer of the skin that has undergone curative therapy or adequately treated carcinoma in situ without evidence of disease.
  3. Participants with known .
  4. Prior solid organ transplantation.
  5. Active or prior documented or inflammatory disorders. The following are exceptions to this criterion:

    1. Participants with vitiligo or autoimmune alopecia.
    2. Participants with autoimmune hypothyroidism (eg, following Hashimoto thyroiditis) stable on hormone replacement.
    3. Any chronic inflammatory or autoimmune skin condition that does not require systemic therapy.
    4. Participants without active disease in the last 5 years may be included, but only after consultation with the Sponsor.
    5. Participants with coeliac disease controlled by diet alone.
  6. Stroke, intracranial haemorrhage, or seizure within 6 months of apheresis.
  7. Cardiac arrhythmias, (such as multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which are symptomatic or require treatment ( [CTCAE] Grade 3) unless controlled by pacemaker (discussion with the Study Physician required); symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
  8. Investigator judgement of one or more of the following:

    1. Mean resting interval > 470 ms, obtained from triplicate (ECGs) performed at screening.
    2. History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and be associated with Torsades de Pointe.
    3. Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
  9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active known infection, cardiomyopathy of any aetiology, symptomatic congestive heart failure defined by class ≥ 3), interstitial lung disease, uncontrolled hypertension, uncontrolled diabetes mellitus, unstable angina pectoris, history of myocardial infarction within the past 6 months prior to apheresis, known bleeding diathesis such as haemophilia, von Willebrand disease, etc.
  10. Active, uncontrolled epilepsy. Participants without active/uncontrolled epilepsy in the last 5 years may be included.
  11. Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss) after consultation with the Study Physician or Medical Monitor. Participants with Grade 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician or Medical Monitor.
  12. Seropositive for (HIV).
  13. Active infection (HCV). Participants testing positive for HCV antibody are eligible only if the polymerase chain reaction is negative for HCV RNA.
  14. Participants with virus (HBV) may be included under the following circumstances:

    1. Negative for hepatitis B surface antigen (HbsAg) and positive for anti-HBc antibody
    2. Positive for HbsAg, but for > 6 months have had normal transaminases and HBV DNA levels between 0 - 2000 IU/mL (inactive carrier state) and willing to start and maintain antiviral treatment for at least the duration of the study.
    3. HBV DNA levels > 2000 IU/mL but on prophylactic antiviral treatment for the past 3 months and will maintain the antiviral treatment during the study.
  15. Local requirements for the testing for infectious diseases and exclusions of applicable participants should be followed per local regulations.

    Prior/Concomitant Therapy

  16. Participants may not receive full-dose long-acting oral (eg, warfarin) or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose from the time of to 28-days post infusion of AZD0754. Use of short acting direct oral anticoagulants (eg, rivaroxaban) for therapeutic and prophylactic purposes are permitted.
  17. Received the following:

    1. Major surgery within 2 weeks prior to apheresis, or planned major surgery within 4 weeks of the study treatment administration (Note: participants with planned surgical procedures to be conducted under local anaesthesia may participate after discussion with the Sponsor).
    2. (except inhaled corticosteroids) or other immunomodulators (including interleukins, interferons, and thymosins) of systemic therapeutic dose, and systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent \< 7 days prior to apheresis.
  18. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy targeted therapy, biologic therapy, tumour embolisation, or monoclonal antibodies, product) within 5 half-lives or ≤ 21 days (whichever is shorter) prior to apheresis. Radiotherapy within 14 days. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy. If sufficient time has not occurred due to the schedule or PK properties of an agent, a longer washout period will be required, as agreed by AstraZeneca and the Investigator.
  19. Any concurrent anticancer treatment with the following exceptions:

    1. Protocol-defined LDC
    2. Hormonal therapy for non cancer-related conditions (eg, hormone replacement therapy)
    3. Androgen deprivation therapy with a luteinising-hormone replacement hormone agonist/antagonist is required if needed to maintain testosterone level in the castration range (levels \< 50 ng/dL) and should be continued (unless bilateral orchiectomy) throughout the trial. Following apheresis, bridging therapy is permitted (if required) as outlined in Section 6.1.2
  20. Participants should not have received any within 30 days prior to apheresis. Participants can receive coronavirus (COVID)-19 vaccines, at the discretion of the Investigator, following a benefit/risk evaluation for the individual participant and in accordance with local rules and regulations and vaccination guidelines. Note: If a COVID-19 vaccine is administered, it should ideally be done at least one week prior to LDC or after completion of the DLT period.

    Prior/Concurrent Clinical Study Experience

  21. Prior treatment with a CAR-T therapy directed at any target or any therapy that is targeted to STEAP2.
  22. Participants with a known life-threatening allergy, , or intolerance to AZD0754 or any of the of the product, including dimethylsulfoxide.

In addition to the above, the following exclusion criteria is applicable for study participants in Australia:

- Participants with human T-lymphotropic virus (HTLV).

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AZD0754

    AZD0754 monotherapy for treatment of participants with metastatic prostate cancer.

    Biological: AZD0754

  • Experimental
    AZD2287

    AZD2287 is a novel imaging agent for STEAP2

    Biological: AZD2287

Interventions

  • BiologicalAZD0754

    Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754. During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy. Study treatment will include lymphodepleting chemotherapy. After lymphodepleting chemotherapy AZD0754 is administered intravenously and patients will be required to stay at the hospital for a protocol specified monitoring period.

  • BiologicalAZD2287

    This is an Optional arm of the study, which subjects will separately consent to if they would like to participate. Subjects will receive doses of a radioactive imaging agent called AZD2287 followed by SPECT/CT imaging scans at two time points.

06

What researchers measure

Primary outcomes

  1. Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).

    Determine if treatment with AZD0754 is safe and tolerable through assessment of DLTs/DLT-like events, AEs, AESIs, SAEs, and changes from baseline in laboratory parameters, vital signs, and ECGs.

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Prostate-specific antigen (PSA) response rate - PSA50

    PSA50 response rate is defined as the proportion of participants achieving a ≥ 50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later.

    Time frame: Through study completion, an average of 2 years

  2. PSA response rate - PSA90

    PSA90 response rate is defined as the proportion of participants achieving a ≥ 90% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later.

    Time frame: Through study completion, an average of 2 years

  3. Duration of PSA Response (DoPSA50, DoPSA90)

    Time from the date of first documented PSA50 and PSA90 until the date of documented PSA progression or death due to any cause in the absence of PSA progression.

    Time frame: Through study completion, an average of 2 years

  4. Durable PSA Response Rate (DRRPSA50, DRRPSA90)

    Percentage of participants who have a confirmed PSA50 and PSA90 response with a duration of at least 6 months.

    Time frame: Through study completion, an average of 2 years

  5. Time to PSA Response (TTPSA50, TTPSA90)

    Time from AZD0754 infusion date until the date of the first documented PSA50 and PSA90 response.

    Time frame: Through study completion, an average of 2 years

  6. Time to PSA Progression (TTPSAP50, TTPSAP90)

    Time from the date of first documented PSA50 and PSA90 response until the date of documented PSA progression.

    Time frame: Through study completion, an average of 2 years

  7. Best Overall Response (BOR)

    Best overall radiological visit response the participant achieves per RECIST V1.1 and PCWG3.

    Time frame: Through study completion, an average of 2 years

  8. Objective Response Rate (ORR)

    Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR).

    Time frame: Through study completion, an average of 2 years

  9. Time to Response (TTR)

    Time from AZD0754 infusion date until date of first documented evidence of CR or PR.

    Time frame: Through study completion, an average of 2 years

  10. Duration of Response (DoR)

    Time from the date of first documented evidence of CR or PR until date of first documented disease progression or death.

    Time frame: Through study completion, an average of 2 years

  11. Durable Response Rate (DRR)

    Percentage of participants who have a confirmed response (CR/PR) with a duration of at least 6 months.

    Time frame: Through study completion, an average of 2 years

  12. Disease Control Rate (DCR)

    Percentage of participants who have a confirmed CR, PR, or Stable Disease (SD) for at least 11 and 23 weeks after AZD0754 infusion.

    Time frame: 12 and 24 weeks after AZD0754 infusion

  13. Percentage change in tumor size

    Percentage change in tumor size from baseline per RECIST V1.1 and PCWG3.

    Time frame: Through study completion, an average of 2 years

  14. Radiographic Progression-free Survival (rPFS)

    Time from AZD0754 infusion until date of objective disease progression according to RECIST V1.1 and PCWG3 criteria.

    Time frame: Through study completion, an average of 2 years

  15. Overall Survival (OS)

    Time from AZD0754 infusion until death due to any cause

    Time frame: Through study completion, an average of 2 years

  16. Time from AZD0754 Infusion to the first Symptomatic Skeletal-related Events (SSRE)

    Time from AZD0754 Infusion to the first Symptomatic Skeletal-related Event (SSRE).

    Time frame: Through study completion, an average of 2 years

  17. Pharmacokinetics - maximum observed serum concentration (Cmax) of AZD0754

    Maximum observed serum concentration

    Time frame: Through study completion, an average of 2 years

  18. Pharmacokinetics - time taken to reach maximum serum concentration (Tmax) of AZD0754

    Time taken to reach maximum serum concentration

    Time frame: Through study completion, an average of 2 years

  19. Pharmacokinetics - Last measurable serum concentration (Clast) of AZD0754

    Last measurable serum concentration

    Time frame: Through study completion, an average of 2 years

  20. Pharmacokinetics - time of last measurable serum concentration (Tlast) of AZD0754

    Time of last measurable serum concentration

    Time frame: Through study completion, an average of 2 years

  21. Pharmacokinetics - Exposure of AZD0754

    Area Under the concentration time curve

    Time frame: Through study completion, an average of 2 years

  22. Biomarker - STEAP2 expression in Tumor

    Investigate STEAP2 expression in tumor as measured by IHC.

    Time frame: Through study completion, an average of 2 years

07

Study locations

10 of 15 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Research Site
    Westwood, Kansas 66205, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Research Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Research Site
    New York, New York 10032, United States
    Recruiting
  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Research Site
    Dallas, Texas 75235, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    East Melbourne, 3002, Australia
    Recruiting
  • Research Site
    Pamplona, 31008, Spain
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Nov 2026, 32 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 32 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Feb 20, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Nov 24, 2026
CompletionEst.
Nov 24, 2026
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06267729
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Mar 12, 2024
Primary completion
Nov 24, 2026 (estimated)
Completion
Nov 24, 2026 (estimated)
Last update
Feb 23, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion